Michel De Wilde is a board member with the Infectious Disease Research Institute and a former senior vice president of research and development at Sanofi Pasteur, in the company's human vaccines division. While at Sanofi, De Wilde led the development and approval by the FDA of several vaccines: Adacel (tetanus-diphtheria-pertussis); Menactra (meningitis); the first prototype H5 pandemic vaccine; and Pentacel (diphtheria-tetanus-pertussis-polio-influenza). Previously, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines), where he held a number of positions, including vice president of research and development, and played a key role in the development of several new vaccines, such as the recombinant hepatitis B vaccine and GSK's malaria vaccine candidate. De Wilde has authored over 50 publications and received his B.S. and Ph.D. from the Free University of Brussels. He was a postdoctoral fellow at the University of Wisconsin, Madison, and the University of Ghent, in Belgium.